Renal Cysts
Drug-induced complex renal cysts — the distinctive ALK-inhibitor lesion, classically crizotinib. Usually asymptomatic, dose/duration-related, and they tend to regress when the drug is stopped.
Where it strikes
Fine-tuning of Na, K, Mg, acid & water
Agents’ overall severity
Each agent’s whole-drug severity grade, not the severity of this lesion specifically — an agent whose signature injury is elsewhere can still be graded severe here.
Agents’ onset window
How soon each agent’s kidney toxicity typically appears — a whole-drug tempo, not specific to this lesion.
Management approach
Full framework →Usually asymptomatic and dose/duration-related; monitor, rarely act.
Drug-level levers
- Continue therapy in most cases; the cysts often regress when the drug is stopped.
- Hold and reassess only for complex cysts with concerning features or complications.
Pharmacologic toolkit
- No specific therapy — Surveillance imaging; intervention only for symptomatic or complicated cysts.
When to biopsy
Not routine; image characterization (and urology input) for complex or enlarging cysts to exclude malignancy.
Monitoring
- · Surveillance imaging as clinically indicated
Educational use only. Educational synthesis of the published literature — not a treatment protocol, dosing guide, or medical advice. Regimens and agents shown are illustrative of what the literature describes; verify against current guidelines (ASON / KDIGO / ASCO / NCCN) and individualize to the patient. Using this site creates no clinician–patient relationship.
Offending agents
Signature offenders
1Agents for which renal cysts is the defining renal lesion.
Also associated
1Agents that cause renal cysts as a secondary pattern alongside a different signature lesion.